デュッセルドルフ
His experience spans various industries, with a particular focus on advising companies in the growth and financial services sectors, often with an international scope.
Nico is listed by Legal 500 as a "Rising Star" and a "Recommended Lawyer" in tax law. His clients appreciate his forward-thinking solutions, which he develops proactively and in consensus with the tax authorities to ensure the best outcome for his clients.
Nico Neukam joined Orrick in April 2024 after working for another international law firm for many years.
シアトル
KT assists these companies with their legal needs as they expand, with a focus on corporate governance and venture financing. He also represents venture capital firms seeking to invest in these high growth companies.
KT graduated from the University of Washington School of Law, where he served as a Managing Editor of the Washington Law Review. He also was a member of the Entrepreneurial Law Clinic, where he advised entrepreneurs on early stage general corporate and intellectual property matters.
Prior to attending law school, KT was a graduate student researcher at the University of California, San Francisco. During grad school, he also worked in the technology transfer office where he helped to consult with inventors within the university to assess the patentability and commercialization prospects of their inventions.
New York
Lauren also represents investors and venture capital firms in their investments in technology companies.
Prior to joining Orrick, Lauren was an associate in the Corporate Group at Wilson Sonsini Goodrich & Rosati in New York.
シリコン・バレー
Michael applies his broad experience in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions to each engagement. He has undertaken over 300 venture capital financings raising an estimated $7 billion for his clients, recently assisting Auris Health to raise over $650 million in financings before its sale to J&J for up to $5.75 billion.
He also brings extensive experience negotiating strategic alliances, representing clients in significant collaborations with GSK, Amgen, Schering-Plough, J&J, Daiichi, Astellas, King Pharmaceuticals, and most recently Pfizer, Merck, Baxter and Dainippon Sumitomo Pharma Co., Ltd.
Michael was the lead lawyer on the initial public offerings for Illumina, Neurocrine Biosciences, Cytokinetics, Pain Therapeutics, NeurogesX, Sequana Therapeutics, Ciphergen Biosystems, Argonaut Technologies, and Microcide Pharmaceuticals.
Michael was also the lead lawyer responsible for negotiating many notable biopharmaceutical spin-outs, including Onyx Pharmaceuticals (Chiron-Cetus), Tularik (Genentech), X-Ceptor (Ligand Pharmaceuticals), Metabasis (Gensia Sicor), and as well on the reverse merger of Transcept Pharmaceuticals with Novacea, creating a new publicly traded entity.
ロンドン
Anna has experience working with global companies on a wide variety of privacy, cybersecurity and data protection matters. She has a particular interest in emerging technologies and their intersection with ethical and social issues associated with her practice.
Anna has contributed a number of articles and thought leadership pieces on current data protection, privacy and information law issues.
ミュンヘン
He advises start-ups and scale-ups on their foundation, financing rounds and growth phases as well as on internationalization projects. He also advises VCs and corporate VCs on their investments.
Before starting his legal practice, he also worked as a trainee lawyer for a U.S. law firm in its San Francisco office.
New York
Jake provides strategic advice and counsel to startup founders and high-growth technology companies, as well as venture capital and other private equity funds.
He has broad experience in corporate and transactional matters, including venture capital financings, mergers and acquisitions and corporate formation and governance matters. He works closely with founders and technology company clients from a wide variety of industries to provide outside general counsel services and strategic business insights.
Jake also works extensively with venture capital and other private equity funds in their investment activities in the US and internationally, including early-stage to growth equity financings, mergers and acquisitions and secondary liquidity transactions.
ミュンヘン
He regularly advises founder teams on the establishment of a two-tier U.S./German holding structures, be it in connection with their admission to a U.S. accelerator or be it for better access to early-stage financing opportunities in the richer U.S. funding ecosystem.
During his legal training, Onur had been with the M&A practice of a Big Four accounting firm and the legal department of a major German technology company in Germany and Canada. In 2022, Onur worked from our San Francisco and Menlo Park offices for three months to take a deep-dive into the Silicon Valley's start-up ecosystem.
Santa Monica
Rajan advises high-growth technology companies of all sizes on formation matters, day-to-day corporate governance, and venture capital financings. He works with founders at every stage, from early formation through financing rounds and acquisitions, delivering practical legal solutions tailored to the unique challenges of growing businesses.
Rajan represents a wide variety of technology companies across consumer internet, software, fintech, climatetech, blockchain, edtech and healthtech industries. He also advises investors and leading venture capital firms on their investments in early and high-growth technology companies.
Prior to joining Orrick, Rajan gained extensive experience in corporate law and venture capital transactions at Kirkland & Ellis and Gunderson Dettmer, where he honed his expertise in complex financing and M&A transactions.
Rajan is a proud Oregonian who earned his J.D. from UC Berkeley School of Law and his bachelor's degree in Japanese and International Studies from the University of Oregon.
ミラノ
With a wealth of experience and a deep understanding of the technology and innovation market, Livia regularly advises early and late-stage companies on both single and multi-tranche investment rounds, secondaries, bridge financings, LBOs, buyouts and other types of exits, mergers, and corporate reorganisations. She has worked with international innovative companies from their inception and has also advised many of the key venture capital and private equity investors in the Italian and international markets.
Alongside her focus on technologies, she has acquired specific experience in the healthcare sector by working alongside one of the world-leading groups in the laboratory analysis sector, from its entry onto the national scene to the consolidation of its leadership position in Italy through M&A transactions.
シリコン・バレー
パーキンス氏は、 ブロックチェーンおよび暗号通貨市場において、企業が目標とする破壊的で変革的技術の市場への投入を達成する上での革新的かつ包括的な法的戦略の策定をサポート。また、DAOやNFTの創設、一般的な企業戦略や資金調達戦略、複雑で変化する規制体制のナビゲートにまで渡り対応しており、ブロックチェーンと仮想通貨エコシステムの企業の良きアドバイザーである。
オリックのテクノロジーカンパニーグループの一員として、最先端のテクノロジー企業や投資家へ、一般企業法務、プライベート・ベンチャーキャピタル・ファイナンス、M&Aサービスに関するサポートやアドバイスを提供。米国シリコンバレーの象徴的存在である複数企業と仕事をする機会も多く、企業戦略や資金調達に関するアドバイスを行っている。
また、シリコンバレーと日本を結ぶオリックの国際的なテクノロジー企業に関する業務をリードし、多くの創業者やコーポレートベンチャーキャピタルファンドを代理したシリコンバレーでの経験を生かし、日本に拠点を置く多くのテクノロジー企業や投資家の代理人を務める。
シリコン・バレー
Yael has extensive experience with advising founders, investors and boards of tech and life sciences companies at all stages and advises on cutting edge deals and complex transactions, with a focus on venture capital financings, debt financings, mergers and acquisitions and corporate governance. She practices across a variety of industries, including software and technology, energy, gaming, healthcare and life sciences. Yael’s practice also includes advising venture capital firms and strategic corporate investors in their investments into technology and life sciences companies.
Yael’s broad-based domestic and international experience also includes advising Israeli venture capital funds, high-tech firms and startups while practicing at some of the top-rated firms in Tel Aviv.